Symbols / CVKD $5.86 +10.27% Cadrenal Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
CVKD Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Fundamentals
Scroll to Statements
Market Cap 14.69M Enterprise Value 10.68M Income -13.24M Sales — Book/sh 1.17 Cash/sh 1.60
Dividend Yield — Payout 0.00% Employees — IPO — P/E — Forward P/E -1.50
PEG — P/S — P/B 5.00 P/C — EV/EBITDA -0.79 EV/Sales —
Quick Ratio 2.53 Current Ratio 2.72 Debt/Eq — LT Debt/Eq — EPS (ttm) -6.64 EPS next Y -3.91
EPS Growth — Revenue Growth — Earnings 2026-03-31 ROA -116.44% ROE -260.11% ROIC —
Gross Margin 0.00% Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 2.51M Shs Float 1.98M Short Float 1.44%
Short Ratio 0.61 Short Interest — 52W High 17.50 52W Low 4.21 Beta 1.55 Avg Volume 51.01K
Volume 54.56K Target Price $27.67 Recom Strong_buy Prev Close $5.31 Price $5.86 Change 10.27%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$27.67
Mean price target
2. Current target
$5.86
Latest analyst target
3. DCF / Fair value
$-55.89
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.86
Low
$13.00
High
$45.00
Mean
$27.67

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-07 main HC Wainwright & Co. Buy → Buy $13
2025-05-16 reit HC Wainwright & Co. Buy → Buy $32
2024-11-11 main HC Wainwright & Co. Buy → Buy $32
2024-06-06 reit HC Wainwright & Co. Buy → Buy $3
2024-05-09 reit HC Wainwright & Co. Buy → Buy $3
2024-03-14 reit HC Wainwright & Co. Buy → Buy $3
2023-12-18 init Noble Capital Markets — → Outperform $4
2023-11-20 init HC Wainwright & Co. — → Buy $3
News
RSS: Latest CVKD news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-29 SZOT MATTHEW K Chief Financial Officer — 9,933 $6.97 $69,233
2025-10-27 SZOT MATTHEW K Chief Financial Officer — 3,600 $13.99 $50,364
2025-10-27 PHAM QUANG X Chief Executive Officer — 2,444 $13.99 $34,237
2025-10-13 SZOT MATTHEW K Chief Financial Officer — 3,493 $13.99 $49,011
2025-10-13 PHAM QUANG X Chief Executive Officer — 3,600 $14.02 $50,706
2025-10-06 SZOT MATTHEW K Chief Financial Officer — 107 $13.99 $1,497
2025-10-02 PHAM QUANG X Chief Executive Officer — 500 $14.13 $7,065
2025-10-01 SZOT MATTHEW K Chief Financial Officer — 1,800 $13.99 $25,183
2025-10-01 PHAM QUANG X Chief Executive Officer — 1,300 $14.01 $18,213
2025-09-25 SZOT MATTHEW K Chief Financial Officer — 12,400 $14.00 $174,175
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Revenue
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
Operating Expense
13.46
+22.81%
10.96
+43.60%
7.63
Research And Development
4.10
-2.49%
4.21
+3.03%
4.08
Selling General And Administration
9.35
+38.50%
6.75
+90.27%
3.55
General And Administrative Expense
9.35
+38.50%
6.75
+90.27%
3.55
Other Gand A
9.35
+38.50%
6.75
+90.27%
3.55
Total Expenses
13.46
+22.81%
10.96
+43.60%
7.63
Operating Income
-13.46
-22.81%
-10.96
-43.60%
-7.63
Total Operating Income As Reported
-13.46
-22.81%
-10.96
-43.60%
-7.63
EBITDA
-13.45
-22.77%
-10.96
-31.43%
-8.34
Normalized EBITDA
-13.45
-22.77%
-10.96
-48.46%
-7.38
Reconciled Depreciation
0.01
+265.64%
0.00
-5.05%
0.00
EBIT
-13.46
-22.81%
-10.96
-31.42%
-8.34
Total Unusual Items
—
0.00
+100.00%
-0.96
Total Unusual Items Excluding Goodwill
—
0.00
+100.00%
-0.96
Special Income Charges
—
0.00
+100.00%
-0.74
Other Special Charges
—
—
0.74
Net Income
-13.24
-24.28%
-10.65
-27.45%
-8.36
Pretax Income
-13.24
-24.28%
-10.65
-27.45%
-8.36
Net Non Operating Interest Income Expense
0.22
-27.63%
0.31
+33.30%
0.23
Interest Expense Non Operating
—
0.00
-100.00%
0.02
Net Interest Income
0.22
-27.63%
0.31
+33.30%
0.23
Interest Expense
—
0.00
-100.00%
0.02
Interest Income Non Operating
0.22
-27.63%
0.31
+24.15%
0.25
Interest Income
0.22
-27.63%
0.31
+24.15%
0.25
Other Income Expense
—
—
-0.96
Gain On Sale Of Security
—
—
-0.22
Tax Rate For Calcs
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-13.24
-24.28%
-10.65
-27.45%
-8.36
Net Income From Continuing Operation Net Minority Interest
-13.24
-24.28%
-10.65
-27.45%
-8.36
Net Income From Continuing And Discontinued Operation
-13.24
-24.28%
-10.65
-27.45%
-8.36
Net Income Continuous Operations
-13.24
-24.28%
-10.65
-27.45%
-8.36
Normalized Income
-13.24
-24.28%
-10.65
-43.92%
-7.40
Net Income Common Stockholders
-13.24
-24.28%
-10.65
-27.45%
-8.36
Diluted EPS
—
-8.73
+6.03%
-9.29
Basic EPS
—
-8.73
+6.03%
-9.29
Basic Average Shares
—
1.22
+35.59%
0.90
Diluted Average Shares
—
1.22
+35.59%
0.90
Diluted NI Availto Com Stockholders
-13.24
-24.28%
-10.65
-27.45%
-8.36
Depreciation Amortization Depletion Income Statement
0.01
+265.64%
0.00
-5.05%
0.00
Depreciation And Amortization In Income Statement
0.01
+265.64%
0.00
-5.05%
0.00
Depreciation Income Statement
0.01
+265.64%
0.00
-5.05%
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
4.33
-57.26%
10.12
+18.83%
8.52
+994.77%
0.78
Current Assets
4.32
-57.29%
10.11
+19.08%
8.49
+1067.15%
0.73
Cash Cash Equivalents And Short Term Investments
4.01
-59.99%
10.02
+19.23%
8.40
+25685.61%
0.03
Cash And Cash Equivalents
4.01
-59.99%
10.02
+19.23%
8.40
+25685.61%
0.03
Cash Financial
—
—
—
0.03
Receivables
0.01
-86.64%
0.04
+2.43%
0.04
—
Accrued Interest Receivable
0.01
-86.64%
0.04
+2.43%
0.04
—
Prepaid Assets
—
0.04
-19.40%
0.05
+130.79%
0.02
Current Deferred Assets
0.11
+636.19%
0.01
0.00
-100.00%
0.67
Other Current Assets
0.20
+373.63%
0.04
-19.40%
0.05
+130.79%
0.02
Total Non Current Assets
0.01
-31.62%
0.01
-60.35%
0.03
-46.46%
0.05
Net PPE
0.01
-25.49%
0.01
-70.18%
0.02
-47.78%
0.04
Gross PPE
0.01
-25.49%
0.01
-70.18%
0.02
-47.78%
0.04
Other Properties
0.01
-25.49%
0.01
-70.18%
0.02
-47.78%
0.04
Other Non Current Assets
0.00
-42.85%
0.00
+0.00%
0.00
-36.66%
0.01
Total Liabilities Net Minority Interest
1.59
-40.83%
2.68
+224.59%
0.83
-86.94%
6.33
Current Liabilities
1.59
-40.83%
2.68
+224.59%
0.83
-38.04%
1.33
Payables And Accrued Expenses
0.85
-50.23%
1.72
+720.17%
0.21
-68.43%
0.66
Payables
0.65
-56.69%
1.50
+797.97%
0.17
-58.68%
0.40
Accounts Payable
0.65
-56.69%
1.50
+797.97%
0.17
-58.68%
0.40
Current Accrued Expenses
0.20
-5.02%
0.21
+410.79%
0.04
-83.71%
0.26
Pensionand Other Post Retirement Benefit Plans Current
0.73
-24.14%
0.97
+62.14%
0.60
-1.51%
0.61
Current Debt And Capital Lease Obligation
—
—
0.02
-67.66%
0.07
Current Debt
—
—
—
0.04
Current Capital Lease Obligation
—
0.00
-100.00%
0.02
-4.21%
0.02
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
-100.00%
4.99
Long Term Debt And Capital Lease Obligation
—
—
0.00
-100.00%
0.57
Long Term Debt
—
—
—
0.55
Long Term Capital Lease Obligation
—
—
0.00
-100.00%
0.02
Stockholders Equity
2.74
-63.19%
7.44
-3.29%
7.69
+238.57%
-5.55
Common Stock Equity
2.74
-63.19%
7.44
-3.29%
7.69
+238.57%
-5.55
Capital Stock
0.00
+31.20%
0.00
+105.30%
0.00
-89.41%
0.01
Common Stock
0.00
+31.20%
0.00
+105.30%
0.00
-89.41%
0.01
Preferred Stock
0.00
0.00
0.00
—
Share Issued
2.34
+31.17%
1.78
+105.31%
0.87
+11.93%
0.78
Ordinary Shares Number
2.34
+31.17%
1.78
+105.31%
0.87
+11.93%
0.78
Additional Paid In Capital
41.70
+25.74%
33.16
+45.68%
22.76
+1870.84%
1.15
Retained Earnings
-38.96
-51.46%
-25.72
-70.67%
-15.07
-124.47%
-6.71
Total Equity Gross Minority Interest
2.74
-63.19%
7.44
-3.29%
7.69
+238.57%
-5.55
Total Capitalization
2.74
-63.19%
7.44
-3.29%
7.69
+253.91%
-5.00
Working Capital
2.73
-63.23%
7.43
-3.08%
7.67
+1363.06%
-0.61
Invested Capital
2.74
-63.19%
7.44
-3.29%
7.69
+255.27%
-4.95
Total Debt
—
0.00
-100.00%
0.02
-96.67%
0.64
Net Debt
—
—
—
0.56
Capital Lease Obligations
—
0.00
-100.00%
0.02
-51.07%
0.04
Net Tangible Assets
2.74
-63.19%
7.44
-3.29%
7.69
+238.57%
-5.55
Tangible Book Value
2.74
-63.19%
7.44
-3.29%
7.69
+238.57%
-5.55
Current Notes Payable
—
—
0.00
-100.00%
0.04
Derivative Product Liabilities
—
—
0.00
-100.00%
4.38
Non Current Accrued Expenses
—
—
0.00
-100.00%
0.04
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Operating Cash Flow
-12.60
-71.28%
-7.36
-108.41%
-3.53
Cash Flow From Continuing Operating Activities
-12.60
-71.28%
-7.36
-108.41%
-3.53
Net Income From Continuing Operations
-13.24
-24.28%
-10.65
-27.45%
-8.36
Depreciation Amortization Depletion
0.01
+265.64%
0.00
-5.05%
0.00
Depreciation
0.01
+265.64%
0.00
-5.05%
0.00
Depreciation And Amortization
0.01
+265.64%
0.00
-5.05%
0.00
Other Non Cash Items
—
-0.00
-100.01%
3.01
Stock Based Compensation
1.94
+36.70%
1.42
+99.76%
0.71
Operating Gains Losses
—
—
0.96
Gain Loss On Investment Securities
—
—
0.22
Change In Working Capital
-1.31
-169.99%
1.87
+1198.08%
0.14
Change In Receivables
0.03
+3752.71%
-0.00
+97.57%
-0.04
Change In Prepaid Assets
-0.16
-1652.74%
0.01
+134.22%
-0.03
Change In Payables And Accrued Expense
-1.10
-158.35%
1.88
+505.51%
-0.46
Change In Accrued Expense
-0.24
-144.94%
0.54
+340.77%
-0.23
Change In Payable
-0.85
-163.80%
1.34
+661.98%
-0.24
Change In Account Payable
-0.85
-163.80%
1.34
+661.98%
-0.24
Change In Other Working Capital
-0.09
-536.19%
-0.01
-102.15%
0.67
Change In Other Current Assets
0.00
0.00
-100.00%
0.00
Investing Cash Flow
-0.01
+21.92%
-0.01
-100.89%
-0.00
Cash Flow From Continuing Investing Activities
-0.01
+21.92%
-0.01
-100.89%
-0.00
Net PPE Purchase And Sale
-0.01
+21.92%
-0.01
-100.89%
-0.00
Purchase Of PPE
-0.01
+21.92%
-0.01
-100.89%
-0.00
Capital Expenditure
-0.01
+21.92%
-0.01
-100.89%
-0.00
Financing Cash Flow
6.60
-26.54%
8.98
-24.56%
11.90
Cash Flow From Continuing Financing Activities
6.60
-26.54%
8.98
-24.56%
11.90
Net Issuance Payments Of Debt
—
0.00
+100.00%
-0.25
Issuance Of Debt
—
—
0.00
Repayment Of Debt
—
0.00
+100.00%
-0.25
Long Term Debt Issuance
—
—
0.00
Net Long Term Debt Issuance
—
—
0.00
Short Term Debt Payments
—
0.00
+100.00%
-0.25
Net Short Term Debt Issuance
—
0.00
+100.00%
-0.25
Net Common Stock Issuance
6.87
+33.52%
5.14
-56.79%
11.90
Common Stock Payments
-0.29
0.00
—
Repurchase Of Capital Stock
-0.29
0.00
—
Proceeds From Stock Option Exercised
0.00
-100.00%
4.71
+1785.84%
0.25
Net Other Financing Charges
-0.27
+69.13%
-0.88
—
Changes In Cash
-6.01
-472.04%
1.62
-80.70%
8.37
Beginning Cash Position
10.02
+19.23%
8.40
+25685.61%
0.03
End Cash Position
4.01
-59.99%
10.02
+19.23%
8.40
Free Cash Flow
-12.61
-71.19%
-7.36
-108.40%
-3.53
Change In Interest Payable
—
—
0.00
Common Stock Issuance
7.16
+39.20%
5.14
-56.79%
11.90
Issuance Of Capital Stock
7.16
+39.20%
5.14
-56.79%
11.90
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category